Quantum BioPharma Engages Stocks.news for Investor Relations Services, Signaling Strategic Focus on Market Visibility

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, announced it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. The six-month agreement, valued at US$250,000, includes services such as company profile creation, media distribution, digital community development, news marketing, and lead generation campaigns. IR Agency LLC is arm’s-length to Quantum and holds no direct or indirect equity interest in the company's securities, according to the press release.

This engagement reflects Quantum's strategic effort to enhance its visibility among investors and the broader financial community. The company is dedicated to building a portfolio of innovative assets and biotech solutions for challenging conditions, including multiple sclerosis (MS) and alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models—the underlying mechanism of MS. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% stake as of March 31, 2026, and a royalty agreement that includes 7% of sales until $250 million is reached, then 3% in perpetuity.

The investor relations campaign is a significant investment for a company at the preclinical stage for its lead candidate, underscoring the importance of maintaining investor interest and funding for future clinical trials. By leveraging Stocks.news's services, Quantum aims to increase awareness of its pipeline and recent developments, potentially attracting new investors and partners. The company's focus on challenging therapeutic areas, such as neurodegenerative diseases with high unmet need, positions it in a competitive but promising sector. The agreement also highlights the growing trend of biotech firms using specialized communications platforms to navigate the complex landscape of investor relations. For more details, the full press release is available at https://ibn.fm/iBZrw.

The news matters because it signals Quantum's proactive approach to building market confidence and supporting its long-term development goals. As the company advances its drug candidates, effective communication will be crucial to securing the capital needed for clinical trials and regulatory milestones. Investors should monitor Quantum's progress with Lucid-MS and its royalty stream from UNBUZZD(TM), which provide both near-term revenue potential and long-term upside. The company's newsroom offers updates at https://ibn.fm/QNTM.